The Oxford AstraZeneca vaccine is credited with saving millions of lives but it was also responsible, in rare cases, for serious side-effects - blood clots in the brain - which could be fatal.

The level of benefit from Covid vaccines is well documented. And the Oxford/AstraZeneca vaccine is credited with saving more lives, external in the first year of its use than any other - 6.3m ...

A Covid vaccine compensation scheme could be set up after thousands claimed they have been left disabled as a result of the AstraZeneca jab, The Telegraph has learnt. The Health Secretary is ...

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses.

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD. | As AstraZeneca ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the message that the product frees chronic obstructive pulmonary disease (COPD) patients to leave their bad ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 billion. However many analysts felt the company had paid far too much ...